Telehealth Services Investing Market Research Report

1. Executive Summary

‍

High-level market outlook and investment thesis for the sector

Telehealth has moved from a pandemic-era surge to a durable delivery channel that is increasingly judged on outcomes, integration, and unit economics rather than raw visit volume. The “right to win” is shifting toward providers/platforms that can (a) prove measurable clinical or cost impact, (b) integrate with payer/employer/health-system workflows, and (c) operate efficiently under tightening regulatory and acquisition-cost conditions.

Key signals supporting this thesis:

• Telehealth utilization has stabilized at scale: McKinsey estimated telehealth approached ~17% of outpatient/office visit E&M claims, with the highest penetration in psychiatry (~50%) and substance use treatment (~30%). (McKinsey & Company)
• Supply-side capability is now mainstream: CDC reports telemedicine use among office-based physicians rising from 16.0% (2019) to 80.5% (2021) (a separate CDC QuickStats series shows a similar magnitude). (CDC, CDC)
• Policy tailwinds remain—but are time-boxed: HHS notes Medicare beneficiaries can receive certain telehealth services at home for non-behavioral care through Jan 30, 2026. (telehealth.hhs.gov)
• Controlled-substance prescribing flexibility is extended but not “solved”: DEA/HHS extended COVID-era telemedicine flexibilities for prescribing controlled meds through Dec 31, 2025, with future permanent rules still evolving. (Federal Register, DEA)

Investment implication: value is migrating to “telehealth + orchestration”—i.e., triage, routing, continuity, and measurable outcomes—while pure video visit commoditizes.

‍

Top 3–5 takeaways for expansion strategy

1. Anchor growth in high-fit clinical lines (especially behavioral health and select chronic/specialty programs) where telehealth adoption and repeat engagement are structurally higher. (McKinsey & Company)
   
   
2. De-risk CAC by shifting mix toward covered lives (payer/employer/health-system distribution) and away from heavy DTC paid media dependence.
   
   
3. Differentiate via integration + workflow: win contracts by reducing total cost of care, improving access, and integrating into existing scheduling/EHR/referral flows rather than selling “telehealth visits.”
   
   
4. Build compliance into go-to-market for controlled substances and Medicare rules; treat policy timelines as gating items in forecasting. (telehealth.hhs.gov, Federal Register)
   
   
5. Use M&A/partnerships to fill capability gaps quickly (in-network clinician supply, diagnostics-at-home, care navigation, AI-enabled ops) to improve outcomes and margin.
   
   

‍

Summary of risks and opportunities

Opportunities

• Behavioral health remains the highest-penetration use case, enabling scale with the right clinician supply + retention model. (McKinsey & Company)
  
  
• Mainstream provider adoption means fewer “education barriers”; competitive advantage shifts to experience, trust, and integration. (CDC, CDC)
  
  
• Medicare policy runway through Jan 30, 2026 supports near-term planning for home-based telehealth in many scenarios.  (telehealth.hhs.gov)
  
  

Risks

• Regulatory cliffs: Medicare telehealth flexibility sunsets/changes can materially affect reimbursement and service design after Jan 30, 2026.  (telehealth.hhs.gov)
  
  
• Controlled-substance policy uncertainty after Dec 31, 2025 adds risk to psychiatry/SUD models reliant on tele-prescribing rules. (Federal Register, DEA)
  
  
• Commoditization pressure: as basic video access becomes ubiquitous, margins compress unless you own outcomes, continuity, and operating leverage.

‍

2. Market Landscape Overview

‍

Total Addressable Market, SAM, and growth outlook

TAM (global, broad “telehealth” definition)
Because “telehealth” definitions vary (services-only vs services+platform+RPM+devices; global vs US), TAM is best treated as a range:

• $123.26B (2024) → $455.27B (2030); 24.68% CAGR (2025–2030) (Grand View Research). (Grand View Research)
• $161.64B (2024) → $791.04B (2032); 22.94% CAGR (Fortune Business Insights; also reports North America at 45.76% share in 2024). (Fortune Business Insights)

Adjacent market lens (telemedicine-only vs telehealth)
If you need a narrower subset, Grand View also sizes telemedicine specifically at $141.19B (2024) → $380.33B (2030) with 17.55% CAGR (2025–2030). (Grand View Research)

SAM (practical “what you can actually sell”)
SAM is constrained by: reimbursement eligibility, licensure footprint, clinical scope, and distribution access. A useful way to define SAM for strategy work is:

• SAM ≈ (Covered lives you can contract) × (Eligible service mix) × (Expected utilization) × (Realizable revenue per episode)
  Use stable utilization anchors where available: McKinsey estimated telehealth has approached ~17% of outpatient/office visit E&M claims, with much higher penetration in psychiatry (~50%) and substance use treatment (~30%). (McKinsey & Company)
  
  

‍

Key segments and verticals within telehealth

The sector is best understood as four overlapping arenas:

1. Virtual-first clinical services
   
   

• Urgent/primary triage, episodic care, after-hours coverage
  
  
• Specialty telehealth (derm, women’s health, endocrinology, etc.)
  
  

2. Behavioral health
   
   

• Therapy, psychiatry, SUD programs (highest sustained penetration) (McKinsey & Company)
  
  

3. Remote monitoring & longitudinal programs
   
   

• Chronic care management + RPM + adherence support
  
  
• Increasingly bundled with at-home diagnostics and care navigation
  
  

4. Enterprise enablement platforms
   
   

• Health systems and payers buying workflow, scheduling, intake, routing, analytics, and “hybrid care” infrastructure
  
  

Demand reality: Telehealth is now less about “video visits” and more about access + routing + continuity (i.e., ensuring the right patient gets to the right clinician fast, with documentation and follow-up).

‍

Macroeconomic forces affecting the sector

1) Regulation & reimbursement (major growth gate)

• HHS states Medicare patients can receive telehealth services for non-behavioral care in their home through Jan 30, 2026. (telehealth.hhs.gov)
  
  
• CMS also reiterates that through Jan 30, 2026, Medicare beneficiaries can receive telehealth anywhere (geography/site flexibilities). (Centers for Medicare & Medicaid Services)

2) Tech adoption is no longer the constraint

• Telehealth capability became widespread post-2020; competitive advantage now centers on integration, experience, compliance, and outcomes proof rather than basic access.
  
  

3) Labor costs and capacity constraints

• Providers and payers increasingly use telehealth to mitigate clinician shortages and extend capacity (virtual triage, centralized teams, asynchronous workflows).
  
  

4) Capital markets: shift from growth-at-all-costs to efficiency

• Buyers and investors are pushing toward profitable distribution (covered lives, referral ecosystems) and retention, penalizing models over-dependent on paid media.
  
  

‍

Competitive dynamics: consolidation vs. fragmentation

Fragmented where it matters operationally

• Telehealth is fragmented by: specialty, state licensure footprint, payer contracting, and care model (DTC vs B2B2C vs provider enablement).
  
  

Consolidating at the platform and distribution layer

• As basic telehealth commoditizes, platforms pursue scale via partnerships, integration, and M&A (often to add: clinician networks, diagnostics, navigation, or specialty depth). Grand View’s telemedicine write-up explicitly cites industry consolidation and strategic partnerships among drivers. (Grand View Research)

‍

Market Map Visual of Major Players by Segment

3. M&A Trends and Deal Activity

‍

Notable acquisitions and implied multiples

‍

Recent deal comps (selected):

How to read the multiples above (practitioner note): these ~2–3x revenue comps are consistent with a “disciplined market” where distribution, reimbursability, and retention matter more than topline growth alone.

‍

Private equity and strategic buyer activity levels

Strategics are buying to add distribution and capability (examples above: Teladoc’s BH + preventive/diagnostics moves). (Teladoc Health, Teladoc Health)

Sponsors are active where there’s a clear roll-up or cash-flow thesis—Drake Star points to GTCR’s acquisition of Cloudbreak Health (cited as a standout) alongside larger strategic-led deals. (DrakeStar)

A second key signal from Drake Star: while fundraising volume fell 19% YoY, the average deal size rose to €15.8M, implying capital concentration in more established assets (which tends to support M&A rather than seed proliferation). (DrakeStar)

‍

Valuation benchmarks: revenue and EBITDA multiples by size

Because many telehealth companies are still low/negative EBITDA, revenue multiples remain the most comparable metric across deal types (services-heavy, platform-heavy, hybrid).

Sector-level multiple trend (telemedicine framing):

• Drake Star reports valuation multiples stabilized and rose from ~2.7x to ~3.2x (first stabilization in three years). (DrakeStar)
  
  

Public comps snapshot (EV/Revenue and EV/EBITDA where available)
For a quick public-market “reality check,” a comp aggregator (Morningstar-powered per the page) shows LTM multiples across listed telemedicine/virtual care names (examples include Talkspace, LifeMD, Atrys Health, etc.). Use this as directional context, then validate with your own market data/term sheets. (Multiples)

Rule-of-thumb framing for diligence (use with caution):

• Sub-scale / DTC-heavy models often trade at lower revenue multiples unless retention is exceptional and CAC payback is short.
  
  
• Covered-lives / reimbursed enterprise models can support higher multiples when churn is low and outcomes/cost offsets are defensible.
  (These patterns are consistent with the “fundamentals over hype” shift described by Drake Star.) (DrakeStar)
  
  

‍

Public vs private comparables (what’s diverging)

• Public markets tend to punish uncertainty in unit economics and policy exposure quickly; private deals often price in strategic synergy (distribution, data loop closure, cross-sell).
  
  
• Earnouts are common in private deals (see Truepill, UpLift, Catapult) as buyers hedge performance risk. (Axios, Teladoc Health, Teladoc Health)

‍

Valuation Multiple Table

4. Technology and Innovation Trends

‍

State of digitization and software adoption

Telehealth is no longer “new tech adoption”—it’s a workflow and interoperability problem: embedding virtual care into scheduling, intake, documentation, billing, and referral loops.

• Provider AI adoption is accelerating: The AMA reports physician enthusiasm for “augmented intelligence” is rising (Feb 12, 2025), reflecting a shift from experimentation to operational use—especially around documentation and administrative burden. (American Medical Association)
• Health systems are deploying AI across many use cases: A JAMIA paper surveying Scottsdale Institute member health systems (Fall 2024; 43 responding systems) reports deployment status and perceived success across 37 AI use cases spanning 10 categories. (OUP Academic)

What this means for telehealth operators: differentiation increasingly comes from how well your stack “plugs in” (EHR, eligibility, payments, eRx, prior auth), not from video quality.

‍

Emerging tech disrupting telehealth (what’s actually impacting operations)

A) Generative AI for clinical documentation (“ambient scribes”)

This is the most commercially validated near-term AI application because it targets a direct pain point: clinician time and burnout.

• Mass General Brigham reports ambient documentation tools (genAI scribes) are associated with reductions in physician burnout and improved well-being, based on research published in JAMA Network Open (Aug 21, 2025). (Mass General Brigham, TIME)
• The Harvard Gazette coverage references surveys of 1,400+ clinicians across two large systems tied to the same research storyline. (Harvard Gazette)

Telehealth implication: ambient documentation can reduce “cost per visit” by cutting after-hours charting and improving provider throughput—but requires strong governance (consent, PHI handling, QA).

B) AI triage and care orchestration

AI routing (symptoms → best modality/provider/next step) is becoming the connective tissue between episodic virtual visits and longitudinal programs.

• Rock Health’s 2025 “Innovation Maturity Curve” commentary highlights which digital health trends are maturing and where AI-enabled solutions are moving from hype to practical deployment. (Rock Health)

Telehealth implication: triage + routing is a lever for conversion, appropriate utilization, and retention—and a defensible moat when paired with proprietary outcomes data.

C) Interoperability and API-driven integration (FHIR/TEFCA + eRx + prior auth)

Operational friction is shifting toward data exchange and transaction automation (especially prescribing and authorization).

• ONC’s HTI-4 Final Rule (July 31, 2025) adds certification criteria and standards tied to electronic prescribing, real-time prescription benefit, and electronic prior authorization. (HealthIT.gov, HealthIT.gov)
• Federal Register updates related to HTI and TEFCA-manner exceptions signal continued policy emphasis on scalable exchange and reduced information blocking. (Federal Register)

Telehealth implication: “virtual care that can’t transact” (eRx, benefit checks, PA) loses on both experience and unit economics.

D) Remote monitoring + at-home diagnostics integration

Telehealth value expands materially when paired with objective data (labs, vitals, diagnostics).

• Recent strategic acquisitions in the sector have explicitly targeted at-home testing and preventive workflows as a feeder to longitudinal care programs (e.g., diagnostics + virtual care bundles).
  
  

‍

R&D / product investment benchmarks (practical proxies)

Telehealth firms often report “R&D” differently (technology & development, product, platform costs). Still, public filings show meaningful spend patterns:

• Teladoc’s annual report (SEC filing) provides detail on product/tech investment and risk factors tied to platform development and operations. (SEC)
• Hims & Hers’ 2024 10-K (SEC) describes a proprietary tech stack and algorithmic personalization; use this as a reference point for DTC-style product investment strategy. (SEC, StockLight)

How to benchmark internally (recommended): track engineering/product spend as a % of revenue by function:

• clinical workflow automation
  
  
• growth & conversion tooling (landing, onboarding, payments)
  
  
• interoperability/eRx/PA integration
  
  
• security/compliance engineering
  
  
• data science & experimentation platform
  
  

‍

Cybersecurity and infrastructure risks (and why they’re rising)

Telehealth increases exposure: remote endpoints, third-party tools, identity workflows, payment flows, and PHI-heavy integrations.

• The HHS OCR breach portal tracks reportable breaches impacting 500+ individuals (the definitive public registry). (ocrportal.hhs.gov)
• Large ecosystem incidents can disrupt care and revenue: Reuters reported the Change Healthcare attack affected ~190 million people (a scale signal for ecosystem risk). (Reuters)

Operational takeaway: cybersecurity is a commercial differentiator in enterprise selling (health plans/systems increasingly require SOC2, pen tests, incident response evidence, vendor risk controls).

‍

Build vs. buy opportunities for tech innovation (decision framework)

Build when it’s your moat

• Triage + routing logic (tailored to your populations)
  
  
• Lifecycle engagement + retention models
  
  
• Experimentation and analytics infrastructure (CAC payback, activation, outcomes)
  
  
• Provider productivity tooling (workflow, scheduling, async protocols)
  
  

Buy when speed and compliance matter

• eRx / real-time benefit / prior auth connectors aligned to new standards direction (HTI-4) (HealthIT.gov)
  
  
• Ambient documentation vendors with proven clinical governance and enterprise security (Mass General Brigham, Wall Street Journal)
• RPM/diagnostics partners to accelerate longitudinal program effectiveness

‍

5. Operations & Supply Chain Landscape

‍

In telehealth, “supply chain” does not mean physical logistics in the traditional sense. It refers to the end-to-end flow of clinical capacity, technology, data, and reimbursement that enables a virtual encounter to be delivered profitably and compliantly at scale.

‍

Typical cost structure breakdown (what actually drives margins)

Cost structures vary by model (DTC vs B2B2C vs enterprise enablement), but public disclosures and operator benchmarks show three dominant cost centers.

A) Direct-to-consumer (DTC) telehealth

Representative example: Hims & Hers (2024 public disclosures)

Key insight: In DTC telehealth, marketing is the single largest and most volatile cost driver, making margins highly sensitive to CAC inflation and retention decay.

‍

B) Payer / employer / enterprise telehealth

Key insight: Enterprise models trade higher sales-cycle friction for more stable CAC, longer contracts, and lower churn, improving long-term margin durability.

‍

Supply-side vulnerabilities and strengths

Strengths

• Geographic arbitrage of clinician supply (telehealth enables multi-state coverage where licensure allows).
  
  
• Asynchronous care models (messaging, intake-first workflows) improve provider utilization.
  
  
• Centralized clinical operations outperform distributed clinic models on throughput and consistency.
  
  

Vulnerabilities

• Clinician shortages, especially in psychiatry and certain specialties.
  
  
• State licensure fragmentation, which increases admin overhead and slows scaling.
  
  
• Vendor sprawl (video, eRx, AI tools, messaging) increases operational risk and cost if not tightly governed.
  
  

‍

Labor force trends: shortages, automation, outsourcing

Clinician labor

• Behavioral health remains structurally constrained; competition for licensed clinicians increases cost per visit.
  
  
• Telehealth platforms increasingly compete on provider experience (documentation tools, scheduling flexibility, predictable pay).
  
  

Automation trends

• Ambient documentation and AI-assisted charting reduce after-hours work and improve throughput.
  
  
• AI triage and routing reduce unnecessary clinician time on low-acuity cases.
  
  

Outsourcing

• Common for: credentialing, revenue cycle management (RCM), after-hours support.
  
  
• Risk: loss of quality control and slower iteration if too much core ops is externalized.

‍

Operations benchmark table

Rather than generic “gross margin,” leading operators track telehealth-specific KPIs:

6. Regulatory and Legal Environment

‍

Telehealth is one of the most policy-sensitive sectors in healthcare. Regulation directly determines who can be treated, how services are reimbursed, what technologies can be used, and which growth models are viable. As a result, regulatory literacy is not a compliance function alone—it is a strategic capability.

‍

Core regulatory frameworks affecting telehealth

A) HIPAA & patient privacy (US baseline)

• Telehealth providers must comply with HIPAA privacy and security rules for protected health information (PHI), including data storage, transmission, access controls, and breach notification.
  
  
• Post-pandemic enforcement has tightened: “good-faith” flexibility during COVID has expired, increasing scrutiny on video platforms, messaging tools, AI vendors, and data-sharing partners.
  
  
• Enterprise buyers increasingly require SOC 2, penetration testing, vendor risk assessments, and formal incident response plans as preconditions to contracting.
  
  

Strategic implication: security posture is now a sales enabler, not just a risk mitigant.

‍

B) Medicare & CMS telehealth rules

Medicare policy remains the single largest regulatory swing factor in US telehealth economics.

Key points:

• Medicare beneficiaries can receive telehealth services from their home (not just rural areas or medical facilities) for many services through January 30, 2026.
  
  
• Geographic and originating-site restrictions remain temporarily waived.
  
  
• Behavioral health telehealth has comparatively stronger and more durable reimbursement support.
  
  

Strategic implication: growth plans that assume permanent Medicare flexibility beyond 2026 must include contingency scenarios.

‍

C) State licensure and scope-of-practice rules

• Telehealth providers must generally be licensed in the patient’s state, not the clinician’s state.
  
  
• This creates:
  
  
  
  • Credentialing and compliance overhead
    
    
  • Slower geographic expansion
    
    
  • Fragmented operational scaling
    
    
• Interstate licensure compacts (e.g., for physicians and nurses) help but do not eliminate complexity.
  
  

Strategic implication: licensure operations should be treated as a core operating function, not back-office overhead.

‍

Controlled substances, prescribing, and DEA oversight

This is one of the highest-risk regulatory zones, especially for psychiatry, ADHD treatment, pain management, and substance use disorder (SUD) programs.

Current state:

• The DEA and HHS extended COVID-era telemedicine flexibilities for prescribing controlled substances through December 31, 2025.
  
  
• These extensions allow certain controlled medications to be prescribed via telehealth without an initial in-person visit, subject to guardrails.
  
  

Key uncertainty:

• Permanent DEA rules are still evolving.
  
  
• Future frameworks are expected to include:
  
  
  
  • Special registration pathways
    
    
  • National PDMP (Prescription Drug Monitoring Program) checks
    
    
  • Enhanced documentation and auditability
    
    

Strategic implication: telehealth models heavily reliant on controlled-substance prescribing face binary regulatory risk and should diversify revenue streams or build rapid compliance adaptability.

‍

FDA, FTC, and marketing-related compliance

FDA (software and medical devices)

• Most telehealth platforms are not FDA-regulated medical devices.
  
  
• However, AI-driven diagnostic or decision-support tools may trigger FDA oversight depending on claims and functionality.
  
  

FTC (consumer protection & advertising)

• The FTC actively scrutinizes:
  
  
  
  • Health claims in marketing
    
    
  • Subscription billing practices
    
    
  • Data-sharing disclosures
    
    
• DTC telehealth brands face elevated risk around:
  
  
  
  • Influencer marketing
    
    
  • Implied treatment claims
    
    
  • “Dark pattern” cancellation flows
    
    

Strategic implication: marketing compliance is a material risk surface, especially for consumer-first telehealth.

‍

International considerations (GDPR and beyond)

For companies operating outside the US:

• GDPR imposes stricter consent, data minimization, and data localization rules than HIPAA.
  
  
• Cross-border data transfers require explicit safeguards.
  
  
• Penalties for non-compliance are materially higher than typical US fines.
  
  

Strategic implication: international expansion often requires separate infrastructure, legal frameworks, and product flows, not just localization.

‍

ESG, ethics, and governance pressures

While not always formalized in regulation, ESG expectations increasingly affect enterprise adoption and investor scrutiny.

Key areas:

• Equity of access (language, disability support, broadband constraints)
  
  
• Clinical safety and escalation protocols
  
  
• Responsible AI usage (bias, explainability, audit trails)
  
  
• Data stewardship and transparency
  
  

Strategic implication: ESG performance influences payer contracts, employer adoption, and public-market valuation—even when not mandated by law.

‍

Pending and emerging regulatory issues to monitor

7. Marketing & Demand Generation

‍

Telehealth marketing has moved from “land-grab” to efficiency, trust, and defensibility. Winning strategies now align tightly with regulatory constraints, channel economics, and buyer type (consumer vs payer/employer). Growth is less about volume and more about predictable CAC, retention, and channel durability.

‍

Customer acquisition channels (what actually works)

A) Organic (SEO, content, app store)

Role: Long-term CAC reduction and brand trust
Best for: DTC and specialty lines (BH, dermatology, women’s health, chronic conditions)

• High-performing telehealth brands invest heavily in condition-specific, medically reviewed content rather than generic “telehealth” messaging.
  
  
• Organic channels increasingly outperform paid over time because:
  
  
  
  • Health search intent is persistent
    
    
  • Content compounds
    
    
  • Trust signals matter more than novelty
    
    

Strategic insight: SEO is not “top of funnel marketing”—it is a unit-economics lever that stabilizes CAC as paid channels fluctuate.

‍

B) Paid media (search, social, affiliates)

Role: Scalable demand capture—but volatile
Best for: High-intent conditions, fast testing, early market entry

Benchmarks from large-scale direct-to-patient healthcare spend show:

• Paid search CTR ~8%
  
  
• CPA ~£30 on average, with wide dispersion depending on condition and funnel quality
  
  

Challenges:

• Rising competition in behavioral health and ADHD
  
  
• Increased scrutiny of health claims and influencer marketing
  
  
• Platform policy changes (Google, Meta) affecting health advertisers
  
  

Strategic insight: Paid media is most effective when:

• Paired with strong pre-qualification (eligibility, pricing clarity)
  
  
• Used to validate demand, then gradually de-risked via organic and partnerships
  
  

‍

C) Referral and partnership channels

Role: Lower CAC, higher trust
Best for: Enterprise and regulated service lines

Examples:

• Provider referrals
  
  
• University or campus partnerships
  
  
• Health system co-branded virtual programs
  
  

Strategic insight: Referral channels outperform paid media on retention and LTV, even at lower volume.

‍

D) Employer / payer distribution (B2B2C)

Role: CAC stabilization and scale
Best for: Enterprise telehealth, behavioral health, navigation platforms

• Acquisition costs are embedded in sales cycles rather than per-member ad spend
  
  
• Requires proof of:
  
  
  
  • Access improvement
    
    
  • Utilization
    
    
  • Cost offsets
    
    

Strategic insight: Covered-lives distribution is now the most defensible growth channel in telehealth.

‍

Sales funnel structures by business model

Strategic insight: Funnel optimization in telehealth is more about reducing friction and uncertainty than persuasion.

‍

CAC, LTV, and brand equity benchmarks

Because CAC/LTV is rarely disclosed cleanly, leading indicators are used instead:

• Marketing as % of revenue
  
  
  
  • DTC leaders often exceed 40%+ during growth phases
    
    
• CAC payback period
  
  
  
  • <12 months preferred for DTC
    
    
  • Longer acceptable in enterprise with high retention
    
    
• Retention
  
  
  
  • 90/180-day retention is a stronger LTV predictor than initial conversion
    
    

Brand equity proxies

• Share of organic traffic
  
  
• Repeat visit rate
  
  
• Direct traffic growth
  
  
• App store reviews segmented by modality
  
  

Strategic insight: Telehealth brands with strong trust signals can spend less to grow, even in competitive conditions.

‍

Competitor marketing budgets and media mix (directional)

Key observation: Public disclosures show that for DTC telehealth, marketing is often the largest single expense line, exceeding technology or operations.

‍

Opportunities for centralized and shared marketing ops (especially post-M&A)

In multi-brand or buy-and-build strategies, significant value comes from marketing centralization, not brand elimination.

High-ROI centralization areas:

• Analytics and attribution (single source of truth)
  
  
• Compliance review for claims and advertising
  
  
• Lifecycle CRM and experimentation
  
  
• Creative production and testing infrastructure
  
  
• SEO and content standards
  
  

What not to centralize fully

• Condition-specific messaging
  
  
• Clinical tone and brand voice
  
  
• Trust signals unique to each audience

‍

8. Consumer & Buyer Behavior Trends

‍

Telehealth demand is no longer driven by “availability” alone. It’s increasingly shaped by fit-for-purpose care, trust, speed, and whether the experience integrates into the patient’s real-world journey (Rx, labs, follow-ups, escalation).

‍

Changing customer needs and expectations

Consumers want speed and convenience—but not at the expense of resolution.
J.D. Power’s 2024 Telehealth Satisfaction findings emphasize that telehealth “scores points” for convenience and accessing care quickly, but experiences vary widely across providers and demographics. (Business Wire, J.D. Power)

What “good” increasingly means operationally

• Short time-to-appointment
  
  
• Clear next steps (Rx, labs, follow-up)
  
  
• Trust in clinician competence and privacy
  
  
• Appropriate escalation paths for cases that shouldn’t stay virtual
  
  

‍

Demographic and psychographic shifts

Satisfaction and usage differ meaningfully by segment.
Fierce Healthcare’s summary of the J.D. Power 2024 study reports that the highest satisfaction scores were among Medicaid enrollees, urban residents, and Millennials/Gen Z. (Fierce Healthcare)

Access anxiety is rising (tailwind for telehealth positioning).
A national survey of 1,008 adults (Jan 25–31, 2024) found 67% say access to medical care is a problem where they live (up from 58% in 2021). (pos.org)

Implication for marketing segmentation:

• “Convenience-first” messaging resonates broadly, but trust-first positioning is critical for older, chronic, and higher-acuity cohorts.
  
  
• Younger cohorts respond to speed + transparency (pricing, scheduling), while enterprise buyers prioritize access + outcomes + cost offsets.
  
  

‍

Industry-specific usage and purchasing patterns

Telehealth is now a specialty-weighted channel, not a universal replacement.

Medicare claims patterns (channel-fit reality):

• MedPAC reports that in 2022, 6% of common E&M office visits were delivered via telehealth, while 50% of common psychotherapy services were delivered via telehealth. (MedPAC)

Physician-delivered “telehealth eligible” spending (2024):

• AMA reports that 3.7% of telehealth-eligible physician spending was billed as telehealth (2024), while psychiatrists are a major outlier (31.2% of eligible spending billed as telehealth). (American Medical Association)

What this means for go-to-market

• Behavioral health remains the “stickiest” and most scalable telehealth segment.
  
  
• For primary care/urgent care, telehealth wins when it solves access gaps (after-hours, low-acuity triage) and integrates seamlessly into downstream steps.
  
  

‍

NPS / satisfaction benchmarks and retention indicators

Satisfaction benchmark (J.D. Power 2024):

• Direct-to-consumer (DTC) telehealth platforms: 730 / 1,000
  
  
• Payer-provided telehealth: 708 / 1,000 (Fierce Healthcare)
  
  

But trend direction matters:
Industry coverage of the same study notes satisfaction fell ~1% for DTC telehealth while payer-provided telehealth satisfaction rose ~18% year-over-year (per reported interpretation of the J.D. Power results). (MobiHealthNews, Becker’s Payer Issues | Payer News)

Retention (practical reality):
Public sources rarely give clean retention benchmarks across telehealth models; operators should benchmark retention internally using cohort measures (30/90/180 days) by condition line + channel. The importance of segmentation is reinforced by the wide satisfaction variance across demographics and provider types in J.D. Power reporting. (Business Wire, J.D. Power)

‍

B2C vs B2B buying cycle evolution

B2C (consumer/DTC)

• Shorter purchase cycle, but more price sensitivity and higher churn risk
  
  
• Growth is heavily influenced by CAC volatility and platform ad policies
  
  
• Trust signals (credentials, privacy, clear prescribing policies) are conversion-critical
  
  

B2B2C (payer/employer/health system)

• Longer sales cycle, but stickier relationships when:
  
  
  
  • activation is strong
    
    
  • utilization rises post-launch
    
    
  • outcomes/cost offsets are measurable
    
    
• Satisfaction improvements in payer-provided telehealth suggest buyers are learning how to deliver better experiences over time. (MobiHealthNews, Becker’s Payer Issues | Payer News)

‍

9. Key Risks & Threats

‍

Telehealth’s long-term viability is less threatened by demand than by policy exposure, competitive convergence, and operational fragility. The most material risks are those that can rapidly compress margins, disrupt growth channels, or invalidate business models rather than slow them gradually.

‍

Industry-specific risk factors

A) Regulatory and policy risk (highest impact)

Telehealth remains unusually exposed to time-bound regulatory decisions.

• Medicare telehealth flexibilities (home as originating site, geographic waivers) are currently extended only through January 30, 2026.
  
  
• Controlled-substance tele-prescribing rules remain under temporary extensions, with permanent DEA frameworks still unsettled.
  
  

Why this matters:
Entire service lines (notably psychiatry, ADHD, and SUD programs) can become non-viable or structurally less profitable with limited notice if rules change.

Mitigation signal:
Operators with diversified service mixes, payer contracts, and in-person escalation pathways are less exposed to single-policy cliffs.

‍

B) Pricing pressure and reimbursement compression

As telehealth becomes normalized:

• Payers increasingly treat it as a cost-containment tool, not a premium service.
  
  
• Reimbursement parity is not guaranteed across states or payers.
  
  
• Employers and plans demand proof of cost offsets, not just access.
  
  

Risk manifestation:
Margins compress if operators compete on price without controlling cost per completed visit (CPCV).

‍

C) Customer acquisition volatility (especially DTC)

Direct-to-consumer telehealth is highly exposed to:

• Paid media inflation
  
  
• Platform policy changes (Google, Meta health ad rules)
  
  
• FTC scrutiny of claims and subscriptions
  
  

Risk manifestation:
Sudden CAC spikes can turn profitable cohorts unprofitable within a single quarter.

Mitigation signal:
Lower dependence on paid media, higher share of organic/referral traffic, and strong retention.

‍

Competitive moats and erosion factors

Weak or eroding moats

• Basic video visit functionality (fully commoditized)
  
  
• Generic telehealth branding without specialty focus
  
  
• Undifferentiated provider networks
  
  

Defensible moats (when executed well)

• Covered-lives distribution (payer/employer contracts)
  
  
• Deep integration into clinical workflows (EHR, eRx, prior auth)
  
  
• Proprietary data on utilization, outcomes, and routing
  
  
• High clinician satisfaction and supply stability
  
  

Threat vector:
Large incumbents and health systems can replicate surface features quickly, eroding shallow differentiation.

‍

Key man risk and concentration risk

Clinical and operational concentration

• Dependence on a small group of clinicians or specialty providers
  
  
• Reliance on a single large payer, employer, or referral partner
  
  
• Founder-led clinical or regulatory relationships without institutionalization
  
  

Why it matters:
Loss of key clinicians, contracts, or executives can disrupt capacity and credibility overnight.

Mitigation signal:
Standardized protocols, distributed clinician networks, and formalized payer relationships.

‍

Barriers to entry vs barriers to scale

Low barriers to entry

• Video infrastructure
  
  
• Basic scheduling and messaging
  
  
• Initial DTC launch
  
  

High barriers to scale (where many fail)

• Multi-state licensure operations
  
  
• Enterprise-grade security and compliance
  
  
• Provider supply at scale
  
  
• Claims management and payer contracting
  
  
• Sustained marketing efficiency
  
  

Strategic risk:
New entrants can appear quickly, but few can scale profitably, increasing noise and price competition while compressing margins.

‍

Technology and vendor dependency risk

• Over-reliance on third-party vendors for:
  
  
  
  • Video
    
    
  • eRx
    
    
  • AI documentation
    
    
  • Identity verification
    
    
• Vendor outages or compliance failures can halt care delivery or trigger breaches.
  
  

Risk manifestation:
Revenue disruption, reputational damage, and enterprise contract loss.

Mitigation signal:
Redundancy, vendor risk management, and in-house ownership of core workflows.

‍

Litigation, enforcement, and reputational exposure

Telehealth companies face elevated risk around:

• FTC enforcement (marketing claims, subscriptions)
  
  
• DEA audits (controlled substances)
  
  
• HIPAA breaches and class actions
  
  
• Medical malpractice across state lines
  
  

Why this matters:
Reputational damage spreads faster in healthcare than in most consumer categories and directly affects acquisition, retention, and enterprise sales.

‍

10. Strategic Recommendations

‍

These recommendations are designed for investors and operators (corp dev / PE / platform strategy). They tie directly to the sector’s measurable constraints: distribution durability, clinician capacity, regulatory exposure, and unit economics (CPCV, retention, CAC payback).

‍

Acquisition criteria refinement (financial, cultural, operational)

Financial screen (unit economics first)

• Contribution margin by service line (not blended): margin per completed visit / per member-month
  
  
• CAC payback (DTC) or sales payback + renewal rate (B2B2C)
  
  
• Retention cohorts (30/90/180-day) segmented by condition line + channel
  
  
• Claims performance (for reimbursed lines): paid rate, denial reasons, days in A/R
  
  

Operational screen (scalability and reliability)

• Licensure footprint + credentialing throughput (time-to-onboard clinicians)
  
  
• Provider utilization distribution (avoid averages; identify long-tail underutilization)
  
  
• No-show rate + intake abandonment rate (largest margin leaks)
  
  
• Security/compliance maturity (SOC 2 readiness, vendor risk program, incident response)
  
  

Strategic fit screen (moat-building)

• Durable distribution: covered lives, health system embeds, referral ecosystems
  
  
• Capability expansion: diagnostics-at-home, pharmacy enablement, specialty depth, care navigation
  
  
• Data/analytics strength: ability to prove outcomes and cost offsets
  
  

Cultural integration screen

• Clinical governance style (protocol discipline vs “provider autonomy”)
  
  
• Risk tolerance (especially around prescribing policy, marketing claims)
  
  
• Operating cadence (experiment-driven vs opinion-driven)
  
  

‍

Near-term acquisition targets or partnership suggestions (themes, not a promotional list)

Theme A — In-network behavioral health access

• Targets/partners with health plan contracting and strong clinician supply
  
  
• Why: reduces CAC volatility, strengthens enterprise narrative, and improves retention
  
  

Theme B — Diagnostics-at-home and preventive workflows

• Partnerships that add labs/screening to strengthen longitudinal programs
  
  
• Why: improves outcomes credibility and creates additional engagement touchpoints
  
  

Theme C — Specialty telehealth networks

• Dermatology, women’s health, endocrinology, cardiometabolic follow-up
  
  
• Why: telehealth works best where the physical exam is limited and follow-up is repeatable
  
  

Theme D — Workflow automation / AI ops

• Documentation, triage, routing, scheduling, and RCM optimization
  
  
• Why: directly lowers CPCV and increases capacity without proportional labor growth
  
  

‍

Buy-and-build vs single-anchor strategy (when each wins)

Buy-and-build is optimal when:

• You can centralize “platform functions” across acquisitions:
  
  
  
  • licensure ops
    
    
  • compliance/security
    
    
  • analytics + experimentation
    
    
  • lifecycle marketing
    
    
  • RCM
    
    
• You want multiple condition-line brands that share infrastructure
  
  

Single-anchor is optimal when:

• You already have durable distribution (payer/employer/health system)
  
  
• Bolt-ons are primarily capability adds (BH network, diagnostics, specialty)
  
  
• You can cross-sell with low incremental CAC
  
  

Key decision rule

• If the constraint is distribution, buy an anchor with covered lives.
  
  
• If the constraint is capability/unit economics, buy bolt-ons that lower CPCV and increase retention.
  
  

‍

Strategic capital deployment roadmap (0–6, 6–18, 18–36 months)

0–6 months: stabilize economics and data truth

• Implement a unified operating dashboard:
  
  
  
  • CPCV, provider utilization, no-show, time-to-first-visit
    
    
  • cohort retention, CAC payback, claims paid rate
    
    
• Centralize compliance review for marketing and clinical protocols
  
  
• Build an experimentation system for intake UX + lifecycle messaging
  
  
• Identify top 2 margin leaks (usually: abandonment + no-shows) and fix them first
  
  

Success metric: ability to forecast CAC payback and capacity with confidence.

‍

6–18 months: scale distribution and add capability

• Acquire or partner in 1–2 areas that reduce structural risk:
  
  
  
  • in-network BH
    
    
  • diagnostics-at-home
    
    
  • specialty network depth
    
    
  • workflow automation that lowers CPCV
    
    
• Expand payer/employer activation playbooks (member engagement post-launch)
  
  
• Create “outcomes proof packs” for enterprise renewals:
  
  
  
  • access gains, utilization, cost offsets, satisfaction
    
    

Success metric: growth no longer depends on paid media arbitrage.

‍

18–36 months: build moats and defensible differentiation

• Build longitudinal care programs and orchestration:
  
  
  
  • triage + routing + follow-up + escalation
    
    
• Expand cross-sell portfolio by condition line and buyer type
  
  
• Push deeper enterprise integrations (EHR, eRx, prior auth, eligibility)
  
  
• Standardize quality systems across acquisitions (clinical QA, safety audits)
  
  

Success metric: higher valuation multiple through durable distribution + measurable outcomes.

‍

11. Appendix & Sources

‍

Full list of data sources used in this report (by topic)

Market sizing / growth

• Grand View Research — Telehealth market size ($123.26B in 2024 → $455.27B by 2030; 24.68% CAGR 2025–2030). (Grand View Research)
• Fortune Business Insights — Telehealth market size ($161.64B in 2024 → $791.04B by 2032; 22.94% CAGR; North America share 45.76% in 2024). (Fortune Business Insights)
• McKinsey — Telehealth utilization “approached up to 17%” of outpatient/office E&M claims; psychiatry ~50%, SUD ~30%. (McKinsey & Company)

Policy / reimbursement (U.S.)

• HHS Telehealth Policy Updates — Medicare home-based telehealth (non-behavioral) extended through Jan 30, 2026. (telehealth.hhs.gov)
• CMS Telehealth FAQ (updated Nov 26, 2025) — Medicare telehealth billing details and scope through Jan 30, 2026. (CMS)

Controlled substances / DEA

• Federal Register — “Third Temporary Extension…” through Dec 31, 2025. (Federal Register)
• DEA — Summary and pointer to the Federal Register extension through 2025. (DEA)

Medicare utilization patterns (service-type mix)

• MedPAC panel deck — 2022 share delivered via telehealth: 6% of common E&M office visits; 50% of common psychotherapy services. (MedPAC)
• MedPAC telehealth status material (supporting context). (MedPAC)

Physician specialty telehealth usage

• American Medical Association (AMA) — 2024: 3.7% of telehealth-eligible physician spending billed as telehealth; psychiatrists 31.2%. (American Medical Association)

Consumer satisfaction / reasons for use

• J.D. Power — 2024 U.S. Telehealth Satisfaction Study (payer-provided satisfaction 708, up 18 points YoY; includes reasons for using telehealth). (J.D. Power)
• MobiHealthNews summary of the J.D. Power findings (directional context). (MobiHealthNews)

M&A and valuation commentary

• Drake Star — Telemedicine Report Q1 2025 (deal activity, multiples stabilization, market maturity). (DrakeStar)

Optional / commonly used but often paywalled (not directly cited here unless you provide access)

• PitchBook, CB Insights, Statista, IBISWorld, S&P Capital IQ, Frost & Sullivan (useful for deeper deal comps, private valuation, cohort benchmarks)
  
  

‍

Raw benchmark data used in this workspace

These are the “raw” assets referenced earlier (for charts/tables you requested):

• paid_search_benchmarks.csv (paid search benchmark inputs you provided)
  
  
• telehealth_market_forecast.png (market sizing/forecast visualization)
  
  
• telemedicine_ma_deals_2023_2024.png and digital_health_ma_q1_q3_2024.png (M&A activity visuals)
  
  
• telehealth_market_map_black.png (market map visual)
  
  

‍

Glossary of industry-specific terms

• Telehealth vs Telemedicine: Telehealth is broader (remote care + enablement + monitoring); telemedicine often refers to remote clinical services/visits.
  
  
• TAM / SAM: Total market vs the realistically serviceable portion given constraints (policy, licensure, buyer access).
  
  
• B2B2C: Selling to payer/employer/health system, who then activates end-users.
  
  
• CPCV: Cost per completed visit (delivery unit economics; excludes cancels/no-shows).
  
  
• CAC / LTV: Customer acquisition cost / lifetime value (best tracked by cohort and channel).
  
  
• RCM: Revenue cycle management (coding, claims, denials, collections).
  
  
• Parity laws: State rules affecting whether/how telehealth is reimbursed relative to in-person care.
  
  
• Originating site: Patient location requirement for reimbursement (temporarily expanded for Medicare).
  
  
• PDMP: Prescription Drug Monitoring Program (controlled-substance prescribing oversight).

‍

Disclaimer: The information on this page is provided by HOLD.co for general informational purposes only and does not constitute financial, investment, legal, tax, or professional advice, nor an offer or recommendation to buy or sell any security, instrument, or investment strategy. All content, including statistics, commentary, forecasts, and analyses, is generic in nature, may not be accurate, complete, or current, and should not be relied upon without consulting your own financial, legal, and tax advisers. Investing in financial services, fintech ventures, or related instruments involves significant risks—including market, liquidity, regulatory, business, and technology risks—and may result in the loss of principal. HOLD.co does not act as your broker, adviser, or fiduciary unless expressly agreed in writing, and assumes no liability for errors, omissions, or losses arising from use of this content. Any forward-looking statements are inherently uncertain and actual outcomes may differ materially. References or links to third-party sites and data are provided for convenience only and do not imply endorsement or responsibility. Access to this information may be restricted or prohibited in certain jurisdictions, and HOLD.co may modify or remove content at any time without notice.

‍